Phase III REVEAL Study Shows Promise for Investigational PET Radiotracer in Diagnosing Cardiac Amyloidosis

Bayer announced detailed results from the Phase III REVEAL study, which evaluated the investigational PET radiotracer iodine 124 evuzamitide for diagnosing cardiac amyloidosis. The study met its primary endpoints for sensitivity and specificity, with findings presented at the European Society of Cardiology Congress 2026 and simultaneously published in The Journal of the American Medical Association.